SG11202009866XA - Compositions and methods for cancer or neoplasia assessment - Google Patents

Compositions and methods for cancer or neoplasia assessment

Info

Publication number
SG11202009866XA
SG11202009866XA SG11202009866XA SG11202009866XA SG11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA
Authority
SG
Singapore
Prior art keywords
neoplasia
assessment
cancer
compositions
methods
Prior art date
Application number
SG11202009866XA
Inventor
Athurva J Gore
Jeffrey A Gole
Rui Liu
Original Assignee
Singlera Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singlera Genomics Inc filed Critical Singlera Genomics Inc
Publication of SG11202009866XA publication Critical patent/SG11202009866XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00Reactions of nucleic acids characterised by
    • C12Q2531/10Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113PCR
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
SG11202009866XA 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment SG11202009866XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656820P 2018-04-12 2018-04-12
PCT/US2019/026395 WO2019199696A1 (en) 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment

Publications (1)

Publication Number Publication Date
SG11202009866XA true SG11202009866XA (en) 2020-11-27

Family

ID=68163272

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009866XA SG11202009866XA (en) 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment

Country Status (10)

Country Link
US (1) US20210388445A1 (en)
EP (1) EP3775290A4 (en)
JP (1) JP2021520809A (en)
KR (1) KR20210003795A (en)
CN (1) CN112352057A (en)
AU (1) AU2019253569A1 (en)
CA (1) CA3096668A1 (en)
SG (1) SG11202009866XA (en)
TW (1) TW202012638A (en)
WO (1) WO2019199696A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856903A4 (en) 2018-09-27 2022-07-27 Grail, LLC Methylation markers and targeted methylation probe panel
US11795495B1 (en) * 2019-10-02 2023-10-24 FOXO Labs Inc. Machine learned epigenetic status estimator
WO2021087275A1 (en) * 2019-10-31 2021-05-06 Mayo Foundation For Medical Education And Research Detecting ovarian cancer
CN111833965B (en) * 2019-11-08 2024-06-04 中国科学院北京基因组研究所(国家生物信息中心) Classification method, device and application of urinary sediment genomic DNA
EP4067488A1 (en) * 2019-11-27 2022-10-05 Keio University Upper tract urothelial carcinoma identification method
US20230193395A1 (en) * 2020-03-20 2023-06-22 Singlera Health Technologies (Shanghai) Ltd. Methods and kits for screening colorectal neoplasm
WO2023096674A1 (en) * 2021-11-23 2023-06-01 Pleno, Inc. Encoded assays
TW202328459A (en) * 2021-12-20 2023-07-16 大陸商江蘇鵾遠生物技術有限公司 A tumor detection method and application

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942197A1 (en) * 2000-09-01 2008-07-09 Epigenomics AG Method for determining the methylation degree of certain cytosines in genome DNA in the sequence context 5'-CpG-3'
CN104846092A (en) * 2007-02-21 2015-08-19 奥斯陆大学医院Hf New markers for cancer
WO2008143896A1 (en) * 2007-05-14 2008-11-27 The Johns Hopkins University Methylation markers for prostate cancer and methods of use
US7843254B2 (en) * 2007-10-31 2010-11-30 Texas Instruments Incorporated Methods and apparatus to produce fully isolated NPN-based bandgap reference
WO2009108917A2 (en) * 2008-02-29 2009-09-03 Oncomethylome Sciences, S.A. Markers for improved detection of breast cancer
WO2011112845A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Methods and compositions related to a multi-methylation assay to predict patient outcome
EP4116437A1 (en) * 2012-05-18 2023-01-11 Clinical Genomics Pty. Ltd. A method of screening for colorectal cancer
WO2014130890A1 (en) * 2013-02-21 2014-08-28 Toma Biosciences, Inc. Methods, compositions, and kits for nucleic acid analysis
EP2886659A1 (en) * 2013-12-20 2015-06-24 AIT Austrian Institute of Technology GmbH Gene methylation based colorectal cancer diagnosis
EP3690063A3 (en) * 2014-11-25 2020-11-04 AIT Austrian Institute of Technology GmbH Diagnosis of lung cancer
EP3262191B2 (en) * 2015-02-24 2023-06-14 Zymo Research Corporation Assays to determine dna methylation and dna methylation markers of cancer
EP3350344A1 (en) * 2015-09-17 2018-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer detection methods
CA3022911A1 (en) * 2016-05-05 2017-11-09 Exact Sciences Development Company, Llc Detection of lung neoplasia by analysis of methylated dna

Also Published As

Publication number Publication date
CN112352057A (en) 2021-02-09
JP2021520809A (en) 2021-08-26
TW202012638A (en) 2020-04-01
CA3096668A1 (en) 2019-10-17
AU2019253569A1 (en) 2020-10-29
WO2019199696A1 (en) 2019-10-17
US20210388445A1 (en) 2021-12-16
KR20210003795A (en) 2021-01-12
EP3775290A1 (en) 2021-02-17
EP3775290A4 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
ZA202006627B (en) Methods and compositions for treating cancer
IL277079A (en) Cartyrin compositions and methods for use
SG11202009866XA (en) Compositions and methods for cancer or neoplasia assessment
IL269150A (en) Compositions and methods for treating cancer
ZA202003849B (en) Vcar compositions and methods for use
IL276808A (en) Compositions and methods for cancer treatment
EP3687981A4 (en) Compositions and methods for treating cancer
IL283625A (en) Diagnostic methods and compositions for cancer immunotherapy
IL269157A (en) Compositions and methods for treating cancer
IL271326A (en) Compositions and methods for enhancing cancer radiotherapy
IL274837A (en) Methods and compositions for treating cancers
IL271680A (en) Compositions and methods for inhibiting HMGB1 expression
EP3612222A4 (en) Compositions and methods for treating cancer
EP3600302A4 (en) Methods and compositions for treating cancer
SG11202012435UA (en) Compositions and methods for treating cancer
ZA202001572B (en) Risk determination for neoplasia and cancer
IL260301A (en) Compositions and methods for assessing the risk of cancer occurrence
IL283076A (en) Methods and compositions for cancer immunotherapy
EP3714043A4 (en) Compositions and methods for treating cancer
IL284327A (en) Compositions and methods for inhibiting hmgb1 expression
EP3688023A4 (en) Methods and compositions for cancer treatment
EP3585398A4 (en) Compositions and methods for treating cancer
SG11202106295WA (en) Compositions and methods for cancer therapy
EP3727452A4 (en) Compositions and methods for treating neoplasia
EP3717502A4 (en) Compositions and methods for characterizing cancer